中文名：Motolimod (VTX-2337)
英文名：Motolimod (VTX-2337)
純度：Moligand?，≥99%
貨號(hào)：M413715
Cas號(hào)：926927-61-9
存儲(chǔ)溫度：-20°C儲(chǔ)存
運(yùn)輸條件：超低溫運(yùn)輸
產(chǎn)品介紹：
Information
Motolimod (VTX-2337) Motolimod (VTX-2337) is a selective and potent Toll-like receptor 8 (TLR8) agonist with EC50 of 100 nM, > 50-fold selectivity over TLR7. Phase 2.
Targets
TLR8 100 nM(EC50)
In vitro
VTX-2337 stimulates the production of both TNFα with EC50 of 140 nM and IL-12 with EC50 of 120 nM in PBMCs. In monocytes and mDCs, VTX-2337 selectively induces the production of TNFα and IL-12 via NF-κB activation. VTX-2337 also stimulates IFNγ production from NK cells, augments the lytic function of NK cells and enhances ADCC.
In vivo
In an ovarian cancer mouse model, TX-2337 enhances the effect of pegylated liposomal doxorubicin (PLD).
Cell Research(from reference)
Cell lines：PBMCs or purified NK cells?
Concentrations：~500 nM?
Incubation Time：48 h?
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對(duì)應(yīng)頁(yè)面：https://www.aladdin-e.com/zh_cn/M413715.html
關(guān)鍵字： 莫托利莫德(VTX-2337);2-amino-N,N-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3H-1-benzazepine-4-carboxamide ; 3H-1-Benzazepine-4-carboxamide, 2-amino-n,N-dipropyl-8-(4-(1-pyrrolidinylcarbonyl)phenyl)- ; AKOS027422467
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代碼：688179），專注于科研試劑的研發(fā)、生產(chǎn)和銷售，已陸續(xù)建立多個(gè)工廠和研發(fā)中心。作為領(lǐng)軍企業(yè)，阿拉丁始終堅(jiān)持質(zhì)量第一，連續(xù)13年被評(píng)為“最受歡迎試劑品牌”。
阿拉丁目前常備庫(kù)存試劑產(chǎn)品品種超過7萬(wàn)種，SKU總數(shù)超過46萬(wàn)，產(chǎn)品線涵蓋了化學(xué)試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個(gè)領(lǐng)域，是國(guó)內(nèi)少數(shù)化學(xué)試劑到生物試劑全面發(fā)展的國(guó)產(chǎn)試劑品牌，產(chǎn)品同步發(fā)布在我們國(guó)內(nèi)外電商平臺(tái)。